Indiana companies prepping for burst of acquisitions
Conditions are ripe for a barrage of mergers and acquisitions to take place this year.
Health Care & Life Sciences
Articles
DeCoudreaux leaving Lilly for top job at Mills College
Alecia DeCoudreaux, the top attorney for Eli Lilly and Co.’s U.S. unit and an active community volunteer, will leave to become president of Mills College in California on July 1.
Daniels’ budget proposal wouldn’t cut hearing aids
State budget director Adam Horst said he misspoke when he told the State Budget Committee last week that Daniels&’ proposal would eliminate Medicaid coverage for hearing aids.
Carmel firm gets FDA approval for lice treatment
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
Health chief: Indiana needs more trauma center access
State Health Commissioner Greg Larkin says much of Indiana lacks the access to hospital trauma centers needed to treat victims of attacks like the one in Tucson that left U.S. Rep. Gabrielle Giffords of Arizona critically injured.
Evans dreams big as Clarian becomes IU Health
Clarian Health, which is set to change its name to Indiana University Health on Jan. 24, is relying on the academic expertise of its downtown Indianapolis hospitals to pull in patients from a wider swath of the state and the nation.
Down on luck, Lilly finds comfort in pets
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
Community Health plans $12M east-side medical complex
Construction is set to begin soon on Community Health Pavilion, a three-story, 55,000-square-foot medical building to be built on six acres at 7910 E. Washington St.
Endocyte prices IPO stock
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
Panel says Lilly’s Solpura isn’t ready for approval
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
LAMKIN: Health care reform is opportunity to reorganize services
Indiana should take advantage of the opportunity to build a comprehensive exchange.
Can video games be good for your health?
Local companies are embedding stealthy video messages for high school and college students.
UPDATE: Judge adds probation to Guidant device plea deal
A Minnesota judge has signed off on a plea agreement that calls for Boston Scientific Corp.'s Guidant unit to pay $296 million for failing to properly disclose changes made to some implantable heart devices, but added three years of probation to the deal.
Roche back in court as partner looks to sell to competitor
Roche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving word the company is speeding up plans to sell itself to Roche rival Alere Inc.
Guidant to appear in federal court for sentencing
Boston Scientific Corp.'s Guidant unit hopes to end a criminal case accusing it of failing to properly disclose changes made to some implantable heart devices when it appears in court Wednesday.
Deal could give Lilly full diabetes deck
Eli Lilly and Co.’s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
Q&A: Derek Bang
Derek Bang, practice leader of health care advisory services at the Crowe Horwath accounting firm in Indianapolis, spent a week in March studying health care in the United Kingdom, especially its universal health care program. He was surprised by the “daily barrage of criticism” he heard about the National Health Service, but also found that the United Kingdom and United States face very similar issues when it comes to constraining growth in health care costs.
UPDATE: Analysts praise Lilly diabetes deal with Boehringer
The deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with five drugs and payments to be named later—but analysts and investors generally liked what they heard.
Lilly agrees to pay up to $1.2B for diabetes drugs
A complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
Lilly partner moves up timetable for diabetes drug
Amylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable and submit a heart-safety study to regulators by the end of 2011, its CEO said.